Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Radiation. Surgery. Department of Surgery, Duke University Medical Center , Durham, North Carolina, United States



Survival: 18.5 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
Radiation
Surgery
   
Drugs:
Country: United States
   
City/State/Province: Durham, North Carolina
   
Hospital: Department of Surgery, Duke University Medical Center
   
Journal: Link
   
Date: 3/2002

Description:
Patients: This Phase II study involved 33 newly diagnosed glioma patients comprised of 27 glioblastoma multiform patients, 4 anaplastic astrocytoma patients, and 2 anaplastic oligodendroglioma patients.

Treatment: Treatment consisted of surgery, 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities (in the brain), followed by external beam radiotherapy and alkylator-based chemotherapy. The 131I-labeled (radioiodinated) antitenascin monoclonal antibody 81C6 was grown in athymic mice.

Toxicity: Toxicities were primarily hematologic and neurologic. Nine patients (27%) developed grade 4 hematologic toxicity before initiation of systemic chemotherapy. Five patients had thrombocytopenia and grade 4 neutropenia. Three patients developed neurologic toxicity (equal to or greater than grade 3). Five patients developed irreversible (over 6 months) neurologic toxicity. Specific neurological defecits (grade 3 and above) affected motor, sensory, and speech functions. New onset, controllable seizures developed in four patients after the 131I-labeled antitenascin monoclonal antibody 81C6 therapy. Other toxicities occurred during the chemotherapy phase of the treatment and included: thrombosis, infection, diarrhea, pulmonary toxicity (grade 4), and hepatic toxicity (grade 4). Two patients died of infection while receiving systemic chemotherapy.

Results: Median survival for the glioblastoma patients (measured from the date of initial treatment) was 79.4 weeks (18.5 months).

Correspondence: David A. Reardon, MD

E-mail to a Friend Email Physician More Information